Suppression of monocyte inflammatory and coagulopathy responses in HIV infection

The increased access globally to effective antiretroviral therapy (ART) among people living with HIV (PLHIV) has led to a change in the demographics of this population (1,2). Once considered a death sentence, HIV infection has now evolved to be a chronic disease with PLHIV achieving near normal life-expectancy (3), despite disparities that still exist between high-income and low-and-middle-income settings (4).